TY - JOUR
T1 - Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era
T2 - A multicenter retrospective study
AU - Marra, Giancarlo
AU - Karnes, Robert Jeffrey
AU - Calleris, Giorgio
AU - Oderda, Marco
AU - Alessio, Paolo
AU - Palazzetti, Anna
AU - Battaglia, Antonino
AU - Pisano, Francesca
AU - Munegato, Stefania
AU - Munoz, Fernando
AU - Filippini, Claudia
AU - Ricardi, Umberto
AU - Linares, Estefania
AU - Sanchez-Salas, Rafael
AU - Goonewardene, Sanchia
AU - Dasgupta, Prokar
AU - Challacombe, Ben
AU - Popert, Rick
AU - Cahill, Declan
AU - Gillatt, David
AU - Persad, Raj
AU - Palou, Juan
AU - Joniau, Steven
AU - Smelzo, Salvatore
AU - Piechaud, Thierry
AU - Taille, Alexandre De La
AU - Roupret, Morgan
AU - Albisinni, Simone
AU - van Velthoven, Roland
AU - Morlacco, Alessandro
AU - Vidit, Sharma
AU - Gandaglia, Giorgio
AU - Mottrie, Alexander
AU - Smith, Joseph
AU - Joshi, Shreyas
AU - Fiscus, Gabriel
AU - Berger, Andre
AU - Aron, Monish
AU - Abreu, Andre
AU - Gill, Inderbir S.
AU - Van Der Poel, Henk
AU - Tilki, Derya
AU - Murphy, Declan
AU - Lawrentschuk, Nathan
AU - Davis, John
AU - Gontero, Paolo
N1 - Publisher Copyright:
© 2020
PY - 2021/5
Y1 - 2021/5
N2 - Background: Salvage radical prostatectomy (sRP) historically yields poor functional outcomes and high complication rates. However, recent reports on robotic sRP show improved results. Our objectives were to evaluate sRP oncological outcomes and predictors of positive margins and biochemical recurrence (BCR). Methods: We retrospectively collected data of sRP for recurrent prostate cancer after local nonsurgical treatment at 18 tertiary referral centers in United States, Australia and Europe, from 2000 to 2016. SM and BCR were evaluated in a univariate and multivariable analysis. Overall and cancer-specific survival were also assessed. Results: We included 414 cases, 63.5% of them performed after radiotherapy. Before sRP the majority of patients had biopsy Gleason score (GS) ≤7 (55.5%) and imaging negative or with prostatic bed involvement only (93.3%). Final pathology showed aggressive histology in 39.7% (GS ≥9 27.6%), with 52.9% having ≥pT3 disease and 16% pN+. SM was positive in 29.7%. Five years BCR-Free, cancer-specific survival and OS were 56.7%, 97.7% and 92.1%, respectively. On multivariable analysis pathological T (pT3a odds ratio [OR] 2.939, 95% confidence interval [CI] 1.469–5.879; ≥pT3b OR 2.428–95% CI 1.333–4.423) and N stage (pN1 OR 2.871, 95% CI 1.503–5.897) were independent predictors of positive margins. Pathological T stage ≥T3b (OR 2.348 95% CI 1.338–4.117) and GS (up to OR 7.183, 95% CI 1.906–27.068 for GS >8) were independent predictors for BCR. Limitations include the retrospective nature of the study and limited follow-up. Conclusions: In a contemporary series, sRP showed promising oncological control in the medium term despite aggressive pathological features. BCR risk increased in case of locally advanced disease and higher GS. Future studies are needed to confirm our findings.
AB - Background: Salvage radical prostatectomy (sRP) historically yields poor functional outcomes and high complication rates. However, recent reports on robotic sRP show improved results. Our objectives were to evaluate sRP oncological outcomes and predictors of positive margins and biochemical recurrence (BCR). Methods: We retrospectively collected data of sRP for recurrent prostate cancer after local nonsurgical treatment at 18 tertiary referral centers in United States, Australia and Europe, from 2000 to 2016. SM and BCR were evaluated in a univariate and multivariable analysis. Overall and cancer-specific survival were also assessed. Results: We included 414 cases, 63.5% of them performed after radiotherapy. Before sRP the majority of patients had biopsy Gleason score (GS) ≤7 (55.5%) and imaging negative or with prostatic bed involvement only (93.3%). Final pathology showed aggressive histology in 39.7% (GS ≥9 27.6%), with 52.9% having ≥pT3 disease and 16% pN+. SM was positive in 29.7%. Five years BCR-Free, cancer-specific survival and OS were 56.7%, 97.7% and 92.1%, respectively. On multivariable analysis pathological T (pT3a odds ratio [OR] 2.939, 95% confidence interval [CI] 1.469–5.879; ≥pT3b OR 2.428–95% CI 1.333–4.423) and N stage (pN1 OR 2.871, 95% CI 1.503–5.897) were independent predictors of positive margins. Pathological T stage ≥T3b (OR 2.348 95% CI 1.338–4.117) and GS (up to OR 7.183, 95% CI 1.906–27.068 for GS >8) were independent predictors for BCR. Limitations include the retrospective nature of the study and limited follow-up. Conclusions: In a contemporary series, sRP showed promising oncological control in the medium term despite aggressive pathological features. BCR risk increased in case of locally advanced disease and higher GS. Future studies are needed to confirm our findings.
KW - Open
KW - Prostate cancer
KW - Recurrence
KW - Robotic
KW - Salvage radical prostatectomy
UR - http://www.scopus.com/inward/record.url?scp=85099131097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099131097&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2020.11.002
DO - 10.1016/j.urolonc.2020.11.002
M3 - Article
C2 - 33436329
AN - SCOPUS:85099131097
SN - 1078-1439
VL - 39
SP - 296.e21-296.e29
JO - Urologic Oncology
JF - Urologic Oncology
IS - 5
ER -